Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Photodynamic therapy: status and potential.

T J Dougherty1

  • 1Dept of Radiation Medicine, Roswell Park Memorial Institute.

Oncology (Williston Park, N.Y.)
|July 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targets, targets everywhere--so where are the new antibacterial drugs?

IDrugs : the investigational drugs journal·2005
Same author

American Society of Microbiology - 100th General Meeting.

IDrugs : the investigational drugs journal·2005
Same author

What will genomics bring to the finish line?

IDrugs : the investigational drugs journal·2005
Same author

Why are there no new antibiotics?

Expert opinion on investigational drugs·2005
Same author

98th General Meeting of the American Society for Microbiology. May 17-21, 1998; Atlanta, GA.

Expert opinion on investigational drugs·2005
Same author

Pharmacogenomics--is there a role in antibiotic therapy?

The pharmacogenomics journal·2002
Same journal

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

Oncology (Williston Park, N.Y.)·2026
Same journal

Access to Care and the Affordable Care Act: Why Do Problems Exist 15 Years Later?

Oncology (Williston Park, N.Y.)·2026
Same journal

Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review.

Oncology (Williston Park, N.Y.)·2026
Same journal

Perceived Social Support, Anxiety, and Depression Among Women With Breast Cancer.

Oncology (Williston Park, N.Y.)·2026
Same journal

Before Certainty.

Oncology (Williston Park, N.Y.)·2026
Same journal

Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus-Positive DLBCL: A Rare Concomitant Association.

Oncology (Williston Park, N.Y.)·2026
See all related articles

Photodynamic therapy (PDT) utilizes photosensitizers like Photofrin II (PII) activated by light to generate singlet oxygen, destroying malignant tumors. Clinical trials show encouraging results for various cancers.

Area of Science:

  • Oncology
  • Biochemistry
  • Photochemistry

Background:

  • Photodynamic therapy (PDT) is an emerging cancer treatment modality.
  • PDT employs photosensitizers, which are inactive until activated by light.
  • Photosensitizers generate cytotoxic singlet oxygen upon light activation, leading to localized tissue destruction.

Purpose of the Study:

  • To evaluate the efficacy and safety of Photofrin II (PII) in photodynamic therapy for cancer treatment.
  • To assess the accumulation and retention of PII in malignant tissues.
  • To report on ongoing Phase III clinical trials for PDT of various tumors.

Main Methods:

  • Photofrin II (PII), a porphyrin oligomer mixture, was administered to patients.
  • PII accumulates and is retained in malignant tissues at higher concentrations than surrounding healthy tissues.

Related Experiment Videos

  • Activated by red light delivered via laser and fiber optics, PII generates singlet oxygen to destroy tumor cells.

    • Main Results:

    • Encouraging results have been observed in several thousand cancer patients treated with PII-PDT.
    • PII demonstrates selective accumulation in malignant tissues.
    • Ongoing Phase III trials are evaluating PDT for bladder, esophageal, and bronchial tumors.

    Conclusions:

    • Photodynamic therapy with Photofrin II is a promising approach for cancer treatment.
    • The selective accumulation and light-activated cytotoxicity of PII offer a targeted therapeutic strategy.
    • Further clinical evaluation through Phase III trials is crucial for establishing PDT's role in oncology.